Scientists believe that for the first time, they have linked the gene CUX1 to the development of one in every 100 tumors in cancer patients.
FierceBiotech is now available on iPhone and iPad!
This is the best FierceBiotech reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Android users: We're on track to have an app complete by the end of the year.
Needless to say, both humans and preclinical studies have limitations--we can't spot every error, and there's only so much a mouse model can tell us. But that doesn't mean basic science research and preclinical studies are useless or even irrelevant. What it means is that we have to take new studies with a grain of salt. Scientists know that early research in peer-reviewed literature is largely speculative and exploratory. The challenge for those of us covering this research is sifting through all the releases touting new "scientific breakthroughs" and putting animal studies in context for readers.
Looking over the past year, FierceBiotech Research has put together a report on 5 promising preclinical programs.
Have something to say? Join the conversation at
FierceBiotech's LinkedIn group.
POPULAR COMMENT THREADS
The medical community welcomed a budget deal struck Tuesday night by the U.S. Congress, which, if approved, would restore funding to the National Institutes of Health, among other federal programs, that had been slashed under sequestration earlier this year.
International Stem Cell Corp. has found a new way to genetically reprogram mature cells into an embryonic-like state, a technique the Carlsbad, CA-based company believes is a safer and more efficient way of creating induced pluripotent stem cells.
A gene discovery by researchers at Tel Aviv University may predict which people are likely to benefit from commonly prescribed antidepressants known as selective serotonin reuptake inhibitors.
With resistance to first-line malaria drugs and the emergence of an especially severe form of malaria on the rise, more investment in early science is needed to combat the disease, according to a new report.
GlaxoSmithKline is launching what it calls the Oncology Clinical and Translational Consortium, a collaborative scientific research network intended to advance drug discovery that will include 6 cancer centers around the world.
Stem cell technology developer Cellular Dynamics said Wednesday it will collaborate with the nonprofit Jain Foundation to create induced pluripotent stem cell lines from patients with certain genetic muscular dystrophies in an effort to find stem cell-based therapies for these disorders.
From Our Sister Sites
Two years after a stinging rejection at the hands of the same committee, Bristol-Myers Squibb and AstraZeneca got a warmer reception for their diabetes drug dapagliflozin, winning a recommendation from an FDA advisory panel and brightening their odds of approval for the once-rebuffed therapy.
Earlier this fall, Given Imaging faced down restive shareholder Discovery Group, which urged the Israeli maker of the PillCam endoscopic camera to explore a sale. Now that Covidien will snatch up the company for $860 million, the activist investor has decided to move on.